ATPW
NGEN

Ashton Thomas Private Wealth’s NervGen Pharma NGEN Stock Holding History

Ashton Thomas Private Wealth’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Hold
10,700
– – ﹤0.01% 1435
2026
Q1 		$40.3K Buy
+10,700
New +$46.4K ﹤0.01% 1290

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ashton Thomas Private Wealth's NGEN Position: Q2 2026 in Review

Ashton Thomas Private Wealth held its NervGen Pharma (NGEN) position steady in Q2 2026 at 10,700 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Ashton Thomas Private Wealth first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $40.3K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Ashton Thomas Private Wealth held 10,700 shares of NervGen Pharma worth $22K as of Q2 2026.
  • Ashton Thomas Private Wealth left its NervGen Pharma share count unchanged in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q2 2026, its #1435 holding.
  • Ashton Thomas Private Wealth first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Ashton Thomas Private Wealth's NervGen Pharma position peaked at $40.3K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.